Prevalence of clinically significant liver fibrosis in the general population: A systematic review and metaanalysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population. Methods: We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population. Results: We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2–3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9–8.8%), 3.5% (95% CI, 2.7–4.5), and 1.2% (95% CI, 0.8–1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibited the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE. Conclusions: Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
Abstract
Background/Aims: Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population. Methods: We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population. Results: We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2–3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9–8.8%), 3.5% (95% CI, 2.7–4.5), and 1.2% (95% CI, 0.8–1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibited the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE. Conclusions: Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
참고문헌 (53)
- Devarbhavi H, "Global burden of liver disease : 2023 update", J Hepatol, 79, pp.516~537 (2023)
- Ginès P, "Liver cirrhosis", Lancet, 398, pp.1359~1376 (2021)
- Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of followup", Hepatology, 61, pp.1547~1554 (2015)
- Castera L, "Noninvasive methods to assess liver disease in patients with hepatitis B or C", Gastroenterology, 142, pp.1293~1302 (2012)
- Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
- Lackner C, "Fibrosis and alcohol-related liver disease", J Hepatol, 70, pp.294~304 (2019)
- Noureddin N, "Noninvasive testing using magnetic resonance imaging techniques as outcomes in nonalcoholic steatohepatitis clinical trials : How full is the glass?", Hepatol Commun, 4, pp.141~144 (2020)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update", J Hepatol, 75, pp.659~689 (2021)
- Canivet CM, "Screening for liver fibrosis in the general population : Where do we stand in 2022?", Diagnostics(Basel), 13, pp.91~ (2022)
- Kjaergaard M, "Screening for fibrosis promotes lifestyle changes : A prospective cohort study in 4796 individuals", Clin Gastroenterol Hepatol, 22, pp.1037~1047 (2024)
- European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : Non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
- Anstee QM, "Impact of non-invasive biomarkers on hepatology practice : Past, present and future", J Hepatol, 76, pp.1362~1378 (2022)
- Ginès P, "Population screening for liver fibrosis : Toward early diagnosis and intervention for chronic liver diseases", Hepatology, 75, pp.219~228 (2022)
- Harris R, "Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis : a systematic review", Lancet Gastroenterol Hepatol, 2, pp.288~297 (2017)
- Rethlefsen ML, "PRISMA-S : an extension to the PRISMA statement for reporting literature searches in systematic reviews", J Med Libr Assoc, 109, pp.174~200 (2021)
- DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
- Blanco-Grau A, "Assessing liver fibrosis using the FIB4 index in the community setting", Diagnostics(Basel), 11, pp.2236~ (2021)
- Bernal-Reyes R, "Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic(dysfunction)associated fatty liver disease : An open population study", Rev Gastroenterol Mex(Engl Ed), 88, pp.199~207 (2023)
- Poynard T, "Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers(FibroTest)", BMC Gastroenterol, 10, pp.40~ (2010)
- Zelber-Sagi S, "The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury : a study in the general population", Eur J Gastroenterol Hepatol, 24, pp.262~269 (2012)
- García-Compeán D, "Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?", Ann Hepatol, 19, pp.258~264 (2020)
- Kang KA, "Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population", Aliment Pharmacol Ther, 51, pp.388~396 (2020)
- Nah EH, "Prevalence of liver fibrosis and associated risk factors in the Korean general population : a retrospective cross-sectional study", BMJ Open, 11, pp.e046529~ (2021)
- Halfon P, "Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results", PLoS One, 16, pp.e0254939~ (2021)
- Baba M, "Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness : a cross section study", BMC Gastroenterol, 11, pp.70~ (2011)
- Eskridge W, "Screening for undiagnosed non-alcoholic fatty liver disease(NAFLD)and non-alcoholic steatohepatitis(NASH) : A population-based risk factor assessment using vibration controlled transient elastography(VCTE)", PLoS One, 16, pp.e0260320~ (2021)
- Ramakrishnan A, "Prevalence of abnormal liver tests and liver fibrosis among rural adults in low and middle-income country : A cross-sectional study", EClinicalMedicine, 51, pp.101553~ (2022)
- Trifan A, "High prevalence of liver fibrosis among general population : a Romanian population-based study", Hepatol Commun, 7, pp.e0032~ (2023)
- Sharma A, "Chronic Liver Disease" (2024), StatPearls Publishing
- Man S, "Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations : A nationwide study with 5. 7 million adults in China", Gastroenterology, 165, pp.1025~1040 (2023)
- Hydes TJ, "Liver fibrosis assessed via noninvasive tests is associated with incident heart failure in a general population cohort", Clin Gastroenterol Hepatol, 22, pp.1657~1667 (2024)
- Conti F, "Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease : An Italian community-based population study", Dig Liver Dis, 48, pp.1357~1363 (2016)
- Roulot D, "Liver stiffness values in apparently healthy subjects : influence of gender and metabolic syndrome", J Hepatol, 48, pp.606~613 (2008)
- Caballería L, "High prevalence of liver fibrosis among european adults with unknown liver disease : A population-based study", Clin Gastroenterol Hepatol, 16, pp.1138~1145 (2018)
- Fabrellas N, "Using transient elastography to detect chronic liver diseases in a primary care nurse consultancy", Nurs Res, 62, pp.450~454 (2013)
- Koehler EM, "Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population : The Rotterdam study", Hepatology, 63, pp.138~147 (2016)
- Llop E, "High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort", United European Gastroenterol J, 9, pp.892~902 (2021)
- You SC, "Factors associated with significant liver fibrosis assessed using transient elastography in general population", World J Gastroenterol, 21, pp.1158~1166 (2015)
- Kwok R, "Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements : a prospective cohort study", Gut, 65, pp.1359~1368 (2016)
- Jepsen P, "Alcoholic cirrhosis in Denmark-population-based incidence, prevalence, and hospitalization rates between 1988 and 2005 : a descriptive cohort study", BMC Gastroenterol, 8, pp.3~ (2008)
- Ganne-Carrié N, "Epidemiology of liver cirrhosis", Rev Prat, 67, pp.726~730 (2017)
- Fleming KM, "Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001 : a general population-based study", J Hepatol, 49, pp.732~738 (2008)
- Cheng PN, "Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community", PLoS One, 13, pp.e0206947~ (2018)
- Pennisi G, "Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease(NAFLD)and type 2 diabetes", Hepatology, 78, pp.195~211 (2023)
- Zhang YN, "Liver fibrosis imaging : A clinical review of ultrasound and magnetic resonance elastography", J Magn Reson Imaging, 51, pp.25~42 (2020)
- Fang K, "Global cirrhosis prevalence trends and attributable risk factorsan ecological study using data from 1990-2019", Liver Int, 42, pp.2791~2799 (2022)
- GBD 2017 Cirrhosis Collaborators, "The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet Gastroenterol Hepatol, 5, pp.245~266 (2020)
- Kanwal F, "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease", Gastroenterology, 161, pp.1657~1669 (2021)
- Sterling RK, "AASLD Practice Guideline on imagingbased non-invasive liver disease assessments of hepatic fibrosis and steatosis", Hepatology (2024)[DOI]
- Petta S, "Prevalence and severity of nonalcoholic fatty liver disease by transient elastography : Genetic and metabolic risk factors in a general population", Liver Int, 38, pp.2060~2068 (2018)
- Zhang X, "Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults : Results from NHANES 2017-2018", PLoS One, 16, pp.e0252164~ (2021)
- Harris R, "Obesity is the most common risk factor for chronic liver disease : Results from a risk stratification pathway using transient elastography", Am J Gastroenterol, 114, pp.1744~1752 (2019)
- Harman DJ, "Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice : a cross-sectional study using transient elastography", Aliment Pharmacol Ther, 47, pp.504~515 (2018)